Back to Search

JAEGAK KIM, D.M.D.

D.M.D.

Oral and Maxillofacial Surgery (Dentist)

NPI: 1528592029Individual

Specialties, Licenses & Credentials

Student in an Organized Health Care Education/Training Program

Student in an Organized Health Care Education/Training Program

Code: 390200000X

Oral and Maxillofacial Surgery (Dentist)Primary

Dentist — Oral and Maxillofacial Surgery

Code: 1223S0112X

DL13281(MA)

Clinical Trials (1)

1
Linked Trials
0
Recruiting
0
With Results

Risankizumab Long-term Remission Study

NCT04630652ACTIVE_NOT_RECRUITINGPHASE4PRINCIPAL_INVESTIGATOR

Research & Publications (20)

Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Request Appointment

This provider isn't set up for online booking yet. Once you submit, we'll reach out to their office to arrange secure delivery of your request.

Contact & Hours

Address
850 HARRISON AVE FL 6
BOSTON, MA 02118

Quick Facts

NPI
1528592029
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
2
Locations
1
Clinical Trials
1
Publications
20

Are you this provider?

Claim Your Profile